Levin O S, Bogolepova A N
Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Pirogov Russian National Research Medical University, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(11):99-107. doi: 10.17116/jnevro202012011199.
Stroke is one of the most common neurological diseases with high morbidity, disability and mortality, which is an urgent medical and social problem. Clinically, stroke, depending on its nature and location, causes a wide range of neurological disorders, including movement disorders, as well as a variety of cognitive and neuropsychiatric disorders. There is an emerging need for new approaches to manage patients with cerebrovascular diseases during the pandemic of COVID-19. Rehabilitation measures for the correction of motor and cognitive impairments are very diverse. The use of drugs stimulating the production of neurotrophic factors is considered as a promising direction of pharmacotherapy. Cerebrolysin promotes significant regression of motor and cognitive impairments in the acute and recovery period of ischemic stroke. Based on the data of clinical studies, Cerebrolysin is included in the guidelines for the rehabilitation of patients with stroke in Canada and Germany.
中风是最常见的神经系统疾病之一，具有高发病率、高致残率和高死亡率，是一个紧迫的医学和社会问题。临床上，中风根据其性质和部位，会引发广泛的神经功能障碍，包括运动障碍以及各种认知和神经精神障碍。在新冠疫情期间，对于脑血管疾病患者的管理出现了对新方法的迫切需求。纠正运动和认知障碍的康复措施多种多样。使用刺激神经营养因子产生的药物被认为是药物治疗的一个有前景的方向。脑蛋白水解物在缺血性中风的急性期和恢复期能促进运动和认知障碍的显著消退。基于临床研究数据，脑蛋白水解物被纳入加拿大和德国中风患者康复指南。
